Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: Results from a phase I/II trial

Journal of Translational Medicine

Volumn 9, Issue 1, 2011, Pages

  Baek, Soyoung ^a   Kim, Choung Soo ^b   Kim, Sung Bae ^b   Kim, Yong Man ^b   Kwon, Seog Woon ^b   Kim, YongMan ^c   Kim, HyunSoo ^c   Lee, Hyunah ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c FCB Pharmicell CoLtd   (South Korea)

Author keywords

Breast cancer; Dendritic cell vaccine; Immune response; Phase I II trial; Renal cell carcinoma

Indexed keywords

CD83 ANTIGEN; DENDRITIC CELL VACCINE; GAMMA INTERFERON; GLYCOPROTEIN P 15095; HLA DR ANTIGEN; INTERLEUKIN 12P70; INTERLEUKIN 2; TRANSFORMING GROWTH FACTOR BETA; CANCER VACCINE; EPITOPE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DRUG TOLERABILITY; FEMALE; HUMAN; KIDNEY CARCINOMA; LOW DRUG DOSE; LYMPHOCYTE PROLIFERATION; MALE; NATURAL KILLER CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; UNSPECIFIED SIDE EFFECT; BREAST TUMOR; CELL PROLIFERATION; CLINICAL TRIAL; CYTOLOGY; CYTOTOXICITY; DENDRITIC CELL; ENZYME LINKED IMMUNOSPOT ASSAY; HEMATOPOIETIC STEM CELL; IMMUNOLOGICAL MONITORING; IMMUNOLOGY; IMMUNOTHERAPY; KIDNEY TUMOR; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; SECRETION; T LYMPHOCYTE;

ADULT; AGED; BREAST NEOPLASMS; CANCER VACCINES; CARCINOMA, RENAL CELL; CELL PROLIFERATION; COMBINED MODALITY THERAPY; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSPOT ASSAY; EPITOPES; FEMALE; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOTHERAPY; INTERFERON-GAMMA; INTERLEUKIN-2; KIDNEY NEOPLASMS; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; MONITORING, IMMUNOLOGIC; T-LYMPHOCYTES; YOUNG ADULT;

EID: 80054707651     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-9-178     Document Type: Article

References (25)

1. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998, 392:245-252. 10.1038/32588, 9521319.
2. Trepiakas R, Pedersen AE, Met O, et al. Comparison of alpha-Type-1 polarizing and standard dendritic cell cytokine cocktail for maturation of therapeutic monocyte-derived dendritic cell preparations from cancer patients. Vaccine 2008, 26:2824-2832. 10.1016/j.vaccine.2008.03.054, 18450338.
3. Fernandez NC, Flament C, Crepineau F, et al. Dendritic cells (DC) promote natural killer (NK) cell functions: dynamics of the human DC/NK cell cross talk. Eur Cytokine Netw 2002, 13:17-27.
4. Gerosa F, Baldani-Guerra B, Nisii C, et al. Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med 2002, 195:327-333. 10.1084/jem.20010938, 2193595, 11828007.
5. Mailliard RB, Son YI, Redlinger R, et al. Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function. J Immunol 2003, 171:2366-2373.
6. Munz C, Dao T, Ferlazzo G, et al. Mature myeloid dendritic cell subsets have distinct roles for activation and viability of circulating human natural killer cells. Blood 2005, 105:266-273. 10.1182/blood-2004-06-2492, 15331446.
7. Ferlazzo G, Tsang ML, Moretta L, et al. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med 2002, 195:343-351. 10.1084/jem.20011149, 2193591, 11828009.
8. Piccioli D, Sbrana S, Melandri E, et al. Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J Exp Med 2002, 195:335-341. 10.1084/jem.20010934, 2193592, 11828008.
9. Fearnley DB, Whyte LF, Carnoutsos SA, et al. Monitoring human blood dendritic cell numbers in normal individuals and in stem cell transplantation. Blood 1999, 93:728-736.
10. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000, 18:767-811. 10.1146/annurev.immunol.18.1.767, 10837075.
11. Shortman K, Naik SH. Steady-state and inflammatory dendritic-cell development. Nat Rev Immunol 2007, 7:19-30. 10.1038/nri1996, 17170756.
12. Nicolette CA, Healey D, Tcherepanova I, et al. Dendritic cells for active immunotherapy: optimizing design and manufacture in order to develop commercially and clinically viable products. Vaccine 2007, 25(Suppl 2):B47-60.
13. Mosca PJ, Hobeika AC, Clay TM, et al. A subset of human monocyte-derived dendritic cells expresses high levels of interleukin-12 in response to combined CD40 ligand and interferon-gamma treatment. Blood 2000, 96:3499-3504.
14. Figdor CG, de Vries IJ, Lesterhuis WJ, et al. Dendritic cell immunotherapy: mapping the way. Nat Med 2004, 10:475-480. 10.1038/nm1039, 15122249.
15. Flamand V, Sornasse T, Thielemans K, et al. Vaccination with tumor-antigen-pulsed dendritic cells induces in vivo resistance to a B cell lymphoma. Adv Exp Med Biol 1993, 329:611-616. 10.1007/978-1-4615-2930-9_102, 8379434.
16. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007, 449:419-426. 10.1038/nature06175, 17898760.
17. Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Annu Rev Immunol 2000, 18:245-273. 10.1146/annurev.immunol.18.1.245, 10837059.
18. Schuler G, Schuler-Thurner B, Steinman RM. The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 2003, 15:138-147. 10.1016/S0952-7915(03)00015-3, 12633662.
19. Antony PA, Restifo NP. CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2. J Immunother 2005, 28:120-128. 10.1097/01.cji.0000155049.26787.45, 1242172, 15725955.
20. Hiura T, Kagamu H, Miura S, et al. Both regulatory T cells and antitumor effector T cells are primed in the same draining lymph nodes during tumor progression. J Immunol 2005, 175:5058-5066.
21. Knoechel B, Lohr J, Kahn E, et al. Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen. J Exp Med 2005, 202:1375-1386. 10.1084/jem.20050855, 2212975, 16287710.
22. Nestle FO, Banchereau J, Hart D. Dendritic cells: On the move from bench to bedside. Nat Med 2001, 7:761-765. 10.1038/89863, 11433329.
23. Engell-Noerregaard L, Hansen TH, Andersen MH, et al. Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother 2009, 58:1-14. 10.1007/s00262-008-0568-4, 18719915.
24. Vitale M, Della Chiesa M, Carlomagno S, et al. NK-dependent DC maturation is mediated by TNFalpha and IFNgamma released upon engagement of the NKp30 triggering receptor. Blood 2005, 106:566-571. 10.1182/blood-2004-10-4035, 15784725.
25. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001, 22:633-640. 10.1016/S1471-4906(01)02060-9, 11698225.